Digital Innovation in Pharma: What Will 2026 Bring?
This year will be the turning point from AI “hype” to the adoption of meaningful AI and digital health solutions in pharma. Here four predictions.
presented by
The Role of RWD in Revolutionizing Clinical Trial Design
Using RWD to understand SDOH factors faced by patients with non-small cell lung cancer paves the way for improving health equity and more effective treatments for more people.
presented by
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
presented by
SDOH in Oncology: Mapping Out How Zip Code Can Affect Care Is a Critical Step to Improving Outcomes
For non small cell lung cancer patients, a zip code can mean the difference between diagnosis time and treatment options.
presented by
Using RWD, SDoH and Patient Mapping to Eliminate Blind Spots from the Patient Journey
This article is part of a series on eliminating blind spots in the patient journey by leveraging real-world data.
Augmenting Brain Power: Real-World Data, Advanced Analytics, and the Future of Clinical Trials
The application of AI technology is part of a carefully orchestrated effort dependent on human intelligence, and the collaboration of physicians, disease-specific specialists, nurses, data scientists, and technologists. Done right, these efforts can lead to profound benefits, and offer a promising future for clinical research and patient care.
Data Technology + RWD Are Positive for Rare Disease Treatment
Technology that offers tools that conform, de-identify, link and aggregate data and data science tools like AI, machine learning and advanced analytics, can help those researching rare diseases overcome the hurdles they face in discovery and development.
presented by
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Harnessing Real-World Data and AI to Advance Research and Treatment for Benign Prostatic Hyperplasia
The ability to harness real-world insights at scale empowers life sciences companies and clinicians to develop more targeted therapies, improve patient outcomes, and drive evidence-based innovation in BPH treatment.
presented by
How Can RWD Transform the Patient Journey?
A one-size fits most approach to clinical trial recruitment is no longer effective. A webinar discussion emphasized the need for patient-level data to shape each phase of a drug’s lifecycle, from clinical development to market access.
presented by
Using RWD to Improve Clinical Trial Recruitment, Endpoints, and Inform Market Access Strategies
The webinar, sponsored by PurpleLab and scheduled for May 22, will explore how healthcare sector companies can leverage real world data (RWD) with a focus on lung cancer.
Improving the Patient Journey in Drug Development
PurpleLab and Genentech executives will explore how to leverage real world data to eliminate blind spots in the patient journey — informing every phase of a drug’s lifecycle, from clinical development to market access — in a May 22 webinar.
presented by
Enhanced Direct Enrollment: Georgia Access and the Power of Partnership
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
How Real-World Data Can Support Label Extension And Safer Use Of Novel Therapies
Engaging in data sharing, observational cohort research, and deeper analysis of available data to yield further insights can drive improved results for patients, making label and cohort extension faster and more robust.
How AI is Accelerating the Need for Real World Data in Healthcare and Life Sciences
Considering the lack of high quality data, companies that excel in compiling and managing data effectively are attracting interest from industry partners and distinguishing themselves from their rivals. Here are some of the ways emerging AI applications are fueling and redefining the need for RWD across HCLS.
Federated Models Offer New Paradigm for Data Monetization in Healthcare
A new report by datma explores how companies can use federated data models to scale RWD.
A CEO’s Guide to AI Exploration: Transforming Organizations and Mindsets
Try a variety of LLM-based tools yourself. Understand the risks, limitations, and who is working on putting quality frameworks and guardrails in place. Engage your employees and partners in discussions about what might now be possible.
Ignoring RWD Endangers Drug Development
Enabling RWD-driven drug development accelerates the approval of more effective and affordable treatments. This approach successfully identifies patient patterns and density indicators and maps causal pathways.